RxDoctor Payments Data

J Rauh, MD

Obstetrics & Gynecology · Miles City, MTNPI 1649378530

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 45.6% of the total. Reporting peaked in 2019 at $399 and has fallen 70.7% since, to $117 in 2025.

$1,441in general payments, 2019–2025

Across 78 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$657
  • Lilly USA, LLC$222
  • Novo Nordisk$150
  • Corcept Therapeutics$136
  • Pfizer$99
  • Amgen$82
  • plus $96 from 4 others

What the payments were for

  • Food & beverage$1,435100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,441 in reported general payments places this provider in the 65th percentile of 95 obstetrics & gynecology providers in Montana.

See all obstetrics & gynecology providers in Montana

Medicare billing

Part B allowed, 2024
$74,177
Medicare patients
151
Services billed
1,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$223,798
MounjaroTirzepatide143$153,552
FarxigaDapagliflozin Propanediol59$45,192
TrulicityDulaglutide45$39,228
Repatha SureclickEvolocumab67$37,890
EliquisApixaban48$27,780
JardianceEmpagliflozin37$21,713
Emgality PenGalcanezumab-Gnlm16$16,344
Synjardy XrEmpagliflozin/Metformin Hcl24$14,812
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,986
PremarinEstrogens, Conjugated20$6,906
Tresiba Flextouch U-200Insulin Degludec19$5,621
Levetiracetam38$5,150
Potassium Chloride67$3,359
Estradiol134$2,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$150$224,568186 claims
Lilly USA, LLCMounjaro, Trulicity, Olanzapine$222$193,953224 claims
AstraZenecaFarxiga, Breztri Aerosphere$657$55,17874 claims
PfizerEliquis, Premarin$99$34,68668 claims
AbbVieSynthroid$25$1,75219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 95 obstetrics & gynecology providers in Montana.

Other obstetrics & gynecology in Miles City

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →